CXCR4 and plasma cell myeloma: Integrating CXCR4-directed ERT into auto- or alloSCT strategies for heavily pretreated lymphoproliferative disorders, including lymphomas and multiple myeloma, has achieved remissions in all evaluated patients 33, 38-40.